NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nanjing Immunophage Biomedical Co., Ltd.

Nanjing Immunophage Biomedical Co., Ltd.

Private
NanjingHealthcare & Life Scienceshttp://immunophage.com.cn/

Last Round

Series B

Mar 13, 2023

Total Funding Raised

$89.9M

Company Overview

Nanjing Immunophage Biomedical Co., Ltd. is a biotechnology company that researches and develops innovative medicines for the treatment of cancer, autoimmune diseases, and neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biopharmaceuticaldrug discoverysmall-molecule therapeuticsimmuno-oncologyGPCR-targetingclinical-stage biotechbiotechfirst-in-class drugsantibody platformmedicinal chemistryautoimmune disease treatmentdrug licensinghigh-throughput screeningpharmacokinetic evaluationAI-aided drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanjing Immunophage Biomedical Co., Ltd. Comps

Public and private peers based on sector, stage, and business model.

Nanjing Immunophage Biomedical Co., Ltd. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Nanjing Immunophage Biomedical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 13, 2023
Series A ExtensionSep 29, 2021
Series AMay 11, 2021
Pre SeedMay 1, 2020
StrategicOct 31, 2019

Nanjing Immunophage Biomedical Co., Ltd. Investors

Notable investors and investment history

Nanjing Immunophage Biomedical Co., Ltd. investors
InvestorRounds
Zhongbo JuliSeries B
FountainBridge CapitalSeries A Extension
Daoyuan CapitalSeries A Extension
Yijing CapitalSeries A Extension
Ennovation VenturesStrategic

Nanjing Immunophage Biomedical Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nanjing Immunophage Biomedical Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nanjing Immunophage Biomedical Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNanjing
Year Founded2016
Last FundingMar 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.